The Sneaky International ETF That’s Quietly Outrunning the S&P 500 This Year

International equities have quietly outrun the U.S. market over the past twelve months, and the Fidelity Enhanced International ETF (NYSEARCA:FENI) has ridden that wave hard. The fund returned roughly 32% over the year ending May 1, 2026, with 8% of that coming year-to-date. It makes U.S. investors look up from their S&P 500 index funds and ask whether the “international diversification” lecture they have been ignoring for a decade was actually right.

FENI is Fidelity’s attempt to do international large-cap exposure with an edge. It is a large-cap core international strategy that tries to beat the MSCI EAFE Index through a quantitative, multifactor stock-selection process rather than just hugging the benchmark. The pitch is that you get developed-markets exposure without paying the price of pure passive indexing or the fees of a traditional active manager.

The Slot This ETF Is Built To Fill

Most U.S. portfolios are dramatically overweight U.S. equities. The textbook fix is a developed-markets ex-U.S. fund covering Europe, Japan, Australia, and the rest of EAFE. FENI is built for that slot, with a twist. Instead of weighting companies strictly by market capitalization, the fund tilts toward stocks that score well on factors like quality, value, and momentum, the same kinds of signals quants have been mining for decades.

The return engine first has the underlying cash flows and earnings of large foreign companies, plus whatever currency translation effect the dollar throws off. The second is factor alpha, the bet that systematically buying cheaper, higher-quality, or trending stocks within EAFE will produce a few extra percentage points a year over a plain index. With a net expense ratio of 0.28%, Fidelity is pricing it like a smart-beta product, expensive compared to a vanilla EAFE index fund but cheap relative to active mutual funds charging four times as much.

Has It Actually Worked?

The headline number is hard to argue with. FENI has grown to $3.19 billion in net assets, which suggests advisors and institutions are increasingly comfortable parking real money here. The price closed at $38.63 on May 4, 2026, after a 3% gain over the prior month.

The macro tailwind matters here. The 10-year Treasury yield sits at 4.39%, off the 4.58% peak from May 21, 2025, and the U.S. trade deficit ran $57.3 billion in February 2026. Persistent deficits and a softer rate backdrop tend to weaken the dollar, which mechanically boosts foreign-equity returns when translated back to USD. The VIX at 16.99, down 31% from a month ago, signals the kind of risk-on environment where international equities historically attract capital.

The honest caveat is that we cannot cleanly separate how much of FENI’s 31.66% came from the EAFE benchmark itself, the dollar, and the multifactor overlay. A passive EAFE fund probably captured most of it. The case for FENI rests on whether the factor tilt earns its 0.28% fee over a full cycle, and one good year is not the answer to that question.

Where The Strategy Can Bite You

Three tradeoffs are worth weighing.

1. Factor cycles are long and unforgiving. Quantitative multifactor strategies can underperform plain-vanilla indexes for years at a stretch when value lags growth, or when momentum reverses. Investors who chase FENI after a 31.66% run should expect stretches where it trails the benchmark it is trying to beat.
2. The currency wheel can spin both ways. Today’s weak-dollar setup helps. If the 10Y-2Y spread, currently 0.50%, steepens because Fed cuts pull short rates lower, the dollar can keep softening. If U.S. growth reaccelerates and the dollar rallies, FENI’s USD-denominated return shrinks even when foreign companies do fine in local currency.
3. Tax and tracking complexity. International ETFs pass through foreign withholding taxes, and quantitative turnover can generate higher capital-gains distributions than a passive index. In a taxable account, that drag is real even when the strategy works.

FENI fits as a core developed-markets sleeve for investors who want a quant tilt on top of EAFE exposure and can stomach factor cycles, but anyone counting on the past year’s 31.66% to repeat is buying the chart and ignoring the strategy.